Exelixis announced its Q4 and Fiscal Year 2023 financial results, reporting total revenues of $479.7 million for the quarter and $1.83 billion for the year. The company's GAAP diluted EPS was $0.27 for the quarter and $0.65 for the year, while non-GAAP diluted EPS was $0.33 for the quarter and $0.90 for the year. Exelixis is focused on advancing its cabozantinib franchise and pipeline development.
Total revenues for Q4 2023 were $479.7 million, compared to $423.9 million for the same period in 2022.
Cabozantinib franchise net product revenues in the U.S. were $429.3 million during Q4 2023.
GAAP diluted EPS for Q4 2023 was $0.27, compared to a net loss of $(0.09) per share for the same period in 2022.
Non-GAAP diluted EPS for Q4 2023 was $0.33, compared to a net loss of $(0.03) per share for the same period in 2022.
Exelixis is maintaining its financial guidance for fiscal year 2024.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance